Press Room | News
EN | NL
May 3, 2013
Amakem to Present Additional Data on its Development Candidate, AMA0076, at the ARVO Annual Meeting
Apr 8, 2013
Amakem Sponsors Ophthalmology Chair at KU Leuven
Jan 3, 2013
Amakem Secures €1.4M Grant to Apply its Localized Drug Action Technology in Inflammatory Bowel Diseases (IBD)
Sep 27, 2012
Amakem Initiates Phase 2a Proof of Concept Study with the Rho Kinase (ROCK) Inhibitor AMA0076 in Patients with Glaucoma and Ocular Hypertension under a US IND
Jul 11, 2012
Amakem Appoints Maarten van Geffen as Head of CMC and Operations
May 11, 2012
Amakem Appoints Dr. Steve Pakola as Chief Medical Officer; Dr. George Lasezkay Joins Board of Directors
May 8, 2012
Amakem Presents AMA0076 Data at the 2012 ARVO Annual Meeting
Mar 20, 2012
Jack Elands, CEO at Amakem NV will be presenting at this year’s BioTrinity 2012.
Mar 20, 2012
Amakem Recruits Leading Ophthalmology Experts to Clinical Advisory Board
Feb 2, 2012
Amakem to Present at Glaucoma 360: New Horizons Forum
Nov 2, 2011
Amakem Announces Further Proof-of-Concept Results for its ‘Localized Drug Action’ Platform
Sep 6, 2011
Amakem raises €18m in a Series A round to advance its ophthalmology drug development programs
Nov 15, 2010
Amakem receives 1.28M€ government funding for COPD drug development program
Sep 15, 2010
Amakem’s ROCK inhibitor program delivers proof of concept for the “Localized Drug Action” platform
Feb 11, 2010
Amakem, a new Flemish drug discovery company starts operations for treatments of major chronic diseases